When did POSEIDA THERAPEUTICS INC (PSTX) report earnings last quarter?
POSEIDA THERAPEUTICS INC (PSTX) last reported earnings on 11/7/2024.
POSEIDA THERAPEUTICS INC (PSTX) Earnings History & Surprises
NASDAQ:PSTX • US73730P1084
Current stock price
9.5 USD
-0.06 (-0.63%)
At close:
9.54 USD
+0.04 (+0.42%)
After Hours:
PSTX Earnings overview
Past quarterly earnings results for POSEIDA THERAPEUTICS INC (PSTX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- N/A
- Period
- Q4 / 2024
- EPS Estimate
- -$0.37
- Revenue Estimate
- 17.34M
Last Reported
Most Recent- Release Date
- Nov 7, 2024
- Period
- Q3 / 2024
- EPS Reported
- $0.21
- EPS Surprise
- 150.52%
- Revenue Surprise
- 332.43%
Beat Rate
Last 8 Quarters 75%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2024 | 0.21 | -0.42 | 150.52% | 160.00% | 71.748M | 16.592M | 332.43% | 667.19% |
| Q2 2024 | -0.32 | -0.42 | 23.01% | - | 25.973M | 15.742M | 64.99% | 29.78% |
| Q1 2024 | -0.25 | -0.43 | 41.64% | 44.44% | 28.142M | 11.9M | 136.49% | 172.09% |
| Q4 2023 | -0.27 | -0.39 | 31.42% | 30.77% | 24.995M | 6.783M | 268.49% | 147.48% |
| Q3 2023 | -0.35 | -0.30 | -17.31% | -138.04% | 9.352M | 14.433M | -35.20% | -91.96% |
| Q2 2023 | -0.32 | -0.54 | 40.58% | 53.62% | 20.013M | 5.177M | 286.58% | 641.22% |
| Q1 2023 | -0.45 | -0.46 | 1.96% | 51.61% | 10.343M | 9.563M | 8.16% | 638.79% |
| Q4 2022 | -0.39 | -0.23 | -69.93% | -2,050.00% | 10.1M | 62.921M | -83.95% | -67.63% |
| Q3 2022 | 0.92 | -0.67 | 238.23% | 235.29% | 116.3M | 1.003M | 11,495.21% | - |
| Q2 2022 | -0.69 | -0.78 | 11.57% | 6.76% | 2.7M | 1.08M | 150.00% | - |
| Q1 2022 | -0.93 | -0.68 | -37.11% | -50.00% | 1.4M | 637.5K | 119.61% | - |
| Q4 2021 | 0.02 | -0.35 | 105.64% | 103.45% | 31.2M | 16.15M | 93.19% | - |
| Q3 2021 | -0.68 | -0.76 | 10.31% | -7.94% | - | - | ||
| Q2 2021 | -0.74 | -0.64 | -15.16% | 67.54% | - | - | ||
| Q1 2021 | -0.62 | -0.65 | 4.28% | - | - | - | ||
| Q4 2020 | -0.58 | -0.70 | 17.19% | - | - | - | ||
| Q3 2020 | -0.63 | -0.56 | -12.30% | - | - | - | ||
| Q2 2020 | -2.28 | -1.51 | -51.03% | - | - | - | ||
| Q1 2020 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
61.65%
Max EPS beat (4)
150.52%
Min EPS beat (4)
23.01%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
200.60%
Max Revenue beat (4)
332.43%
Min Revenue beat (4)
64.99%
Analysis
In the last 4 quarters, PSTX has consistently beaten EPS estimates in all releases
PSTX has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, PSTX has beaten the EPS estimates by 61.7% on average.
In the last 4 quarters, PSTX has beaten the revenue estimates by 200.6% on average.
Related analysis
POSEIDA THERAPEUTICS INC / PSTX Earnings FAQ
Can you provide information on whether POSEIDA THERAPEUTICS INC beat earnings estimates in the last quarter?
POSEIDA THERAPEUTICS INC (PSTX) beat EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often POSEIDA THERAPEUTICS INC beats earnings estimates?
In the last 4 quarters, POSEIDA THERAPEUTICS INC (PSTX) has beaten EPS estimates in 4 out of 4 releases.